Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, ...

Both LUNA and OPTIC were designed to assess a broad wet AMD population, including hard-to-treat patients with severe disease ...

Shares of Palatin Technologies, Inc. (PTN) gained 16% on Monday after the company announces completion of patient enrollment in phase ...

KEY POINTS A 72-year-old man presented to the emergency department with a 2-week history of hypotension, postural dizziness, and muscle weakness. He had a medical history of HIV, lipodystrophy, ...

Fortunately, the scan was negative. With the correct diagnosis in hand, we established that his condition was physiological — not psychological — and treated him with intravenous immunoglobulin and ...

When you hear that your dog has an infection, you’re most likely thinking of a bacterial or viral infection. However, viruses ...

A young teacher who suffers from severe asthma has spoken of how patients with the high-risk condition can be left on ...

Incyte to Spotlight New Data, Including a Late Breaking Oral Presentation for Tafasitamab in Follicular Lymphoma, at the 2024 ...

LUNA is an ongoing double-masked, randomized Phase 2 trial. OPTIC is an ongoing, open-label, dose-ranging first-in-human ...

ms10.hinet.net Objectives: To determine the efficacy of a two week and a four week course of oral steroids in the conservative treatment of carpal tunnel syndrome. Methods: 109 patients with carpal ...

Amglidia® has been approved by the European Medicines Agency (EMA) and is commercially available in EuropeStrong strategic fit with Eton’s ...

Many people with sleep apnea benefit from oral devices that pull the lower jaw forward and hold it there, enlarging the ...